|
EP3810189A1
|
|
Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
|
|
US2020353050A1
|
|
Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
|
|
WO2019094265A1
|
|
Pd1 polypeptide binding molecules
|
|
AU2017207282A1
|
|
Interleukin-10 in production of antigen-specific CD8+ T cells and methods of use of same
|
|
AU2016385474A1
|
|
Methods of using interleukin-10 for treating diseases and disorders
|
|
AU2016378387A1
|
|
Interleukin-15 compositions and uses thereof
|
|
KR20180038553A
|
|
Methods for using interleukin-10 to treat diseases and disorders
|
|
WO2016196211A1
|
|
Methods of using interleukin-10 for treating diseases and disorders
|
|
CN107847583A
|
|
PEGylated Interleukin 10 for treating cancer
|
|
WO2016126615A1
|
|
Methods of using interleukin-10 for treating diseases and disorders
|
|
US2017362291A1
|
|
Methods of Improving Yield in Recombinant Protein Production
|
|
US2017246252A1
|
|
Methods of using interleukin-10 for treating diseases and disorders
|
|
KR20170068553A
|
|
Interleukin-15 compositions and uses thereof
|
|
WO2015187295A2
|
|
Methods of lowering serum cholesterol
|
|
WO2015108785A1
|
|
Methods of using interleukin-10 for treating diseases and disorders
|
|
MX2016005915A
|
|
Methods of using interleukin-10 for treating diseases and disorders.
|
|
AU2014311432A1
|
|
Methods of using interleukin-10 for treating diseases and disorders
|
|
EP3434277A1
|
|
Method for assessing protein identity and stability
|
|
AU2014257123A1
|
|
Interleukin-10 compositions and uses thereof
|
|
CN105209054A
|
|
Methods of using interleukin-10 for treating diseases and disorders
|
